A Crossover Pilot Study of the Effect of Amiloride on Proteinuria

• Status: Recruiting
• Trial end date: 2021-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This cross-over study is designed to test the hypothesis that amiloride will reduce urinary protein excretion and protect the kidney from rapid progression in proteinuric kidney disease.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Georgetown University
• Treatments: Amiloride; Triamterene

Criteria

Inclusion Criteria:

• Patient with any type of proteinuric kidney diseases

• Aged 18-75

• Proteinuria ≥1g/day

• estimated glomerular filtration rate (eGFR) ≥ 30ml/min/1.73m2

Exclusion Criteria:

• Clinical evidences of lupus nephritis, or HIV associated nephropathy

• eGFR <30ml/min/1.73m2

• Requirement for treatment with mineralocorticoid receptor antagonists (spironolactone, eplerenone)

• Status post kidney transplant

• Received glucocorticoid steroids within six months

• Serum K >4.8 mmol/L

• Total carbon dioxide <17 mmol/L

• Hemoglobin <10 g/dl

• Contraindicated or allergic to loop diuretics or potassium sparing diuretics

• Abnormal liver function tests